Toll-like receptors in systemic lupus erythematosus: Potential targets for therapeutic intervention

Current Allergy and Asthma Reports

Volumn 12, Issue 1, 2012, Pages 1-7

  Horton, Christopher G ^a,b   Farris, A Darise ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmunity; Lupus; Systemic lupus erythematosus; Targets; Therapeutic intervention; Therapy; TLR; Toll like receptors

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MYELOID DIFFERENTIATION FACTOR 88; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ARTICLE; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; CYTOKINE PRODUCTION; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; NONHUMAN; RNA BINDING; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNITY; DNA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NUCLEIC ACIDS; TOLL-LIKE RECEPTORS;

EID: 84857638052     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-011-0234-3     Document Type: Article

References (80)

1. S Akira S Uematsu O Takeuchi 2006 Pathogen recognition and innate immunity Cell 124 4 783 801 16497588 10.1016/j.cell.2006.02.015 1:CAS:528:DC%2BD28Xit1Kltb8%3D (Pubitemid 43261452)
2. M Yamamoto, et al. 2003 Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway Science 301 5633 640 3 12855817 10.1126/science.1087262 1:CAS:528:DC%2BD3sXlvVKnsLs%3D (Pubitemid 36927946)
3. T Kawai S Akira 2007 TLR signaling Semin Immunol 19 1 24 32 17275323 10.1016/j.smim.2006.12.004 1:CAS:528:DC%2BD2sXjslGrsLY%3D (Pubitemid 46498752)
4. K Hoebe E Janssen B Beutler 2004 The interface between innate and adaptive immunity Nat Immunol 5 10 971 4 15454919 10.1038/ni1004-971 1:CAS:528:DC%2BD2cXnvFCgsr0%3D (Pubitemid 41057712)
5. S Akira K Takeda T Kaisho 2001 Toll-like receptors: critical proteins linking innate and acquired immunity Nat Immunol 2 8 675 80 11477402 10.1038/90609 1:CAS:528:DC%2BD3MXlslGjtLs%3D (Pubitemid 32747155)
6. Y Park, et al. 2004 Association of the polymorphism for Toll-like receptor 2 with type I diabetes susceptibility Ann N Y Acad Sci 1037 170 4 15699513 10.1196/annals.1337.028 1:CAS:528:DC%2BD2MXislWhsL4%3D (Pubitemid 40299762)
7. S Devaraj, et al. 2008 Increased Toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type I diabetes: further evidence of a proinflammatory state J Clin Endocrinol Metab 93 2 578 83 18029454 10.1210/jc.2007-2185 1:CAS:528:DC%2BD1cXit1Snurw%3D (Pubitemid 351240834)
8. HS Kim, et al. 2007 Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes Immunity 27 2 321 33 17707128 10.1016/j.immuni.2007.06.010 1:CAS:528:DC%2BD2sXhtVSgtb3E (Pubitemid 47284922)
9. MK Mohammad, et al. 2006 Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse Int Immunol 18 7 1101 13 16728431 10.1093/intimm/dxl045 1:CAS:528:DC%2BD28XmtFKgtrg%3D (Pubitemid 43923428)
10. MF Roelofs, et al. 2005 The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells Arthritis Rheum 52 8 2313 22 16052591 10.1002/art.21278 1:CAS:528:DC%2BD2MXpslGhtro%3D (Pubitemid 41117415)
11. H Maciejewska Rodrigues, et al. 2009 Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis Mol Immunol 47 1 12 8 19232437 10.1016/j.molimm.2009.01.010 1:CAS:528:DC%2BD1MXhtleksb3O
12. HJ Anders 2005 A Toll for lupus Lupus 14 6 417 22 16038103 10.1191/0961203305lu2102rr 1:CAS:528:DC%2BD2MXnsVCis70%3D (Pubitemid 40961313)
13. SR Christensen, et al. 2005 Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus J Exp Med 202 2 321 31 16027240 10.1084/jem.20050338 1:CAS:528:DC%2BD2MXmsVKhtL8%3D (Pubitemid 41043827)
14. SR Christensen, et al. 2006 Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus Immunity 25 3 417 28 16973389 10.1016/j.immuni.2006.07. 013 1:CAS:528:DC%2BD28XhtVOjtLzN (Pubitemid 44354217)
15. R Lafyatis A Marshak-Rothstein 2007 Toll-like receptors and innate immune responses in systemic lupus erythematosus Arthritis Res Ther 9 6 222 18086320 10.1186/ar2321 (Pubitemid 351753654)
16. S Subramanian, et al. 2006 A Tlr7 translocation accelerates systemic autoimmunity in murine lupus Proc Natl Acad Sci U S A 103 26 9970 5 16777955 10.1073/pnas.0603912103 1:CAS:528:DC%2BD28XmvVajtbY%3D (Pubitemid 43993607)
17. P Pisitkun, et al. 2006 Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication Science 312 5780 1669 72 16709748 10.1126/science.1124978 1:CAS:528:DC%2BD28XlsFeqtb4%3D (Pubitemid 43902669)
18. N Shen, et al. 2010 Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus Proc Natl Acad Sci U S A 107 36 15838 43 20733074 10.1073/pnas.1001337107 1:CAS:528:DC%2BC3cXhtFOru7jM This article describes the first association of TLR7 SNPs and SLE. The authors describe SNPs in TLR7 among Asian populations that associate with SLE, especially in males. This marks an important step in defining a relationship between TLRs and autoimmune disease
19. A Kawasaki, et al. 2011 TLR7 single nucleotide polymorphisms in the 3′ untranslated region and intron independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study Arthritis Res Ther 13 2 R41 21396113 10.1186/ar3277 1:CAS:528: DC%2BC3MXkt1Sksrw%3D This work expanded the studies done by Shen et al. Here, additional SNPs are described, with particular attention paid to their association with SLE in Japanese women
20. EJ Hennessy AE Parker LA O'Neill 2010 Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 9 4 293 307 20380038 10.1038/nrd3203 1:CAS:528:DC%2BC3cXksF2itb4%3D
21. D Jarrossay, et al. 2001 Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells Eur J Immunol 31 11 3388 93 11745357 10.1002/1521-4141(200111)31:11<3388::AID- IMMU3388>3.0.CO;2-Q 1:CAS:528:DC%2BD3MXovVSjsrc%3D (Pubitemid 33100532)
22. N Kadowaki, et al. 2001 Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens J Exp Med 194 6 863 9 11561001 10.1084/jem.194.6.863 1:CAS:528:DC%2BD3MXmvFGgs7g%3D (Pubitemid 32983021)
23. LA O'Neill AG Bowie 2007 The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling Nat Rev Immunol 7 5 353 64 17457343 10.1038/nri2079 (Pubitemid 46674493)
24. R Medzhitov, et al. 1998 MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways Mol Cell 2 2 253 8 9734363 10.1016/S1097-2765(00)80136-7 1:CAS:528:DyaK1cXmtVyisrg%3D (Pubitemid 128373651)
25. GM Barton R Medzhitov 2003 Toll-like receptor signaling pathways Science 300 5625 1524 5 12791976 10.1126/science.1085536 1:CAS:528:DC%2BD3sXktlKru7w%3D (Pubitemid 36682871)
26. T Kawai S Akira 2008 Toll-like receptor and RIG-I-like receptor signaling Ann N Y Acad Sci 1143 1 20 19076341 10.1196/annals.1443.020 1:CAS:528:DC%2BD1MXpvFKrsQ%3D%3D
27. CJ Markin LF Saltibus L Spyracopoulos 2008 Dynamics of the RING domain from human TRAF6 by 15N NMR spectroscopy: implications for biological function Biochemistry 47 38 10010 7 18759459 10.1021/bi800252x 1:CAS:528: DC%2BD1cXhtVGntbbN
28. T Kawai, et al. 2004 Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6 Nat Immunol 5 10 1061 8 15361868 10.1038/ni1118 1:CAS:528:DC%2BD2cXnvFCgs7w%3D (Pubitemid 41057726)
29. N Silverman T Maniatis 2001 NF-kappaB signaling pathways in mammalian and insect innate immunity Genes Dev 15 18 2321 42 11562344 10.1101/gad.909001 1:CAS:528:DC%2BD3MXnsV2hs7o%3D (Pubitemid 32899738)
30. T Taniguchi, et al. 2001 IRF family of transcription factors as regulators of host defense Annu Rev Immunol 19 623 55 11244049 10.1146/annurev.immunol.19.1.623 1:CAS:528:DC%2BD3MXivFKgu78%3D (Pubitemid 32368048)
31. M Colonna 2007 TLR pathways and IFN-regulatory factors: to each its own Eur J Immunol 37 2 306 9 17273997 10.1002/eji.200637009 1:CAS:528: DC%2BD2sXitl2gs7o%3D (Pubitemid 46915569)
32. SM McWhirter, et al. 2004 IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts Proc Natl Acad Sci U S A 101 1 233 8 14679297 10.1073/pnas.2237236100 1:CAS:528: DC%2BD2cXjvFantw%3D%3D (Pubitemid 38084233)
33. •• Chockalingam, A., et al., Negative regulation of signaling by a soluble form of Toll-like receptor 9. Eur J Immunol, 2011. The authors describe a novel, cleaved form of TLR9 that in its soluble form can inhibit signaling through intact TLR9. This suggests an additional endogenous control mechanism of TLR signaling and a potential drug target for treatment of SLE.
34. AT Dulay, et al. 2009 Soluble TLR2 is present in human amniotic fluid and modulates the intraamniotic inflammatory response to infection J Immunol 182 11 7244 53 19454721 10.4049/jimmunol.0803517 1:CAS:528:DC%2BD1MXmtVKqtbY%3D
35. SL Zunt, et al. 2009 Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-alpha secretion by macrophage-like cells Clin Exp Immunol 156 2 285 93 19292767 10.1111/j.1365-2249.2009.03854.x 1:CAS:528:DC%2BD1MXlvVWgtLY%3D
36. O Demaria, et al. 2010 TLR8 deficiency leads to autoimmunity in mice J Clin Invest 120 10 3651 62 20811154 1:CAS:528:DC%2BC3cXht1GgtLfF A function of TLR8 has not been adequately described. Here, Demaria et al. describe an inhibitory role of TLR8 in mice. This article shows that TLR8 acts as an inhibitor of TLR7 expression, and its absence leads to autoimmunity in mice
37. S Janssens, et al. 2003 MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB- and AP-1-dependent gene expression FEBS Lett 548 1-3 103 7 12885415 10.1016/S0014-5793(03)00747-6 1:CAS:528:DC%2BD3sXls1Ont7c%3D (Pubitemid 37281258)
38. K Kobayashi, et al. 2002 IRAK-M is a negative regulator of Toll-like receptor signaling Cell 110 2 191 202 12150927 10.1016/S0092-8674(02)00827-9 1:CAS:528:DC%2BD38XlvV2htrw%3D (Pubitemid 34876547)
39. RR Graham, et al. 2008 Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus Nat Genet 40 9 1059 61 19165918 10.1038/ng.200 1:CAS:528:DC%2BD1cXhtVGgtrfF
40. L Vereecke R Beyaert G van Loo 2009 The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology Trends Immunol 30 8 383 91 19643665 10.1016/j.it.2009.05.007 1:CAS:528:DC%2BD1MXps1Wqurk%3D
41. SK Nanda, et al. 2011 Polyubiquitin binding to ABIN1 is required to prevent autoimmunity J Exp Med 208 6 1215 28 21606507 10.1084/jem.20102177 1:CAS:528:DC%2BC3MXns1Skur0%3D This article discusses the protein ABIN1 as an inhibitor of NF-κB downstream of TLRs. ABIN1 mutant mice develop an autoimmune phenotype that is relieved in MyD88-deficient animals
42. KL Moser, et al. 2009 Recent insights into the genetic basis of systemic lupus erythematosus Genes Immun 10 5 373 9 19440199 10.1038/gene.2009.39 1:CAS:528:DC%2BD1MXptVarur8%3D
43. R Merino L Fossati S Izui 1992 The lupus-prone BXSB strain: the Yaa gene model of systemic lupus erythematosus Springer Semin Immunopathol 14 2 141 57 1475741 10.1007/BF00195291 1:STN:280:DyaK3s7hsl2ltw%3D%3D
44. DH Kono, et al. 2009 Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus Proc Natl Acad Sci U S A 106 29 12061 6 19574451 10.1073/pnas.0905441106 1:CAS:528:DC%2BD1MXps1anu74%3D By using Unc93b mutant mice, these authors showed that production of nucleic acid-specific autoantibodies is dependent on stimulation of nucleic acid-binding TLRs
45. M Herrmann, et al. 1998 Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus Arthritis Rheum 41 7 1241 50 9663482 10.1002/1529-0131(199807)41:7<1241::AID- ART15>3.0.CO;2-H 1:STN:280:DyaK1czis1Kitw%3D%3D (Pubitemid 28313427)
46. Pan, Z.J., et al., TLR7 modulates anti-nucleosomal autoantibody isotype and renal complement deposition in mice exposed to syngeneic late apoptotic cells. Ann Rheum Dis, 2009.
47. H Garcia-Ortiz, et al. 2010 Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population Ann Rheum Dis 69 10 1861 5 20525845 10.1136/ard.2009.124313 1:CAS:528:DC%2BC3cXhtlems7jP This group analyzed the copy number variations of TLR7 among children with SLE compared with healthy controls. They showed that an increase in TLR7 copy numbers was associated with childhood SLE
48. PL De Jager, et al. 2006 Genetic variation in Toll-like receptor 9 and susceptibility to systemic lupus erythematosus Arthritis Rheum 54 4 1279 82 16575840 10.1002/art.21755 (Pubitemid 43672940)
49. JW Hur, et al. 2005 Association study of Toll-like receptor 9 gene polymorphism in Korean patients with systemic lupus erythematosus Tissue Antigens 65 3 266 70 15730519 10.1111/j.1399-0039.2005.00374.x 1:CAS:528:DC%2BD2MXivFars7Y%3D (Pubitemid 40342433)
50. FY Demirci, et al. 2007 Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus J Rheumatol 34 8 1708 11 17516623 1:CAS:528:DC%2BD2sXhtVSkt7bF (Pubitemid 47267614)
51. MW Ng, et al. 2005 Polymorphisms of the toll-like receptor 9 (TLR9) gene with systemic lupus erythematosus in Chinese Rheumatology (Oxford) 44 11 1456 7 10.1093/rheumatology/kei120 1:CAS:528:DC%2BD2MXhtFCjtL7L (Pubitemid 41631873)
52. K Migita, et al. 2007 Toll-like receptor expression in lupus peripheral blood mononuclear cells J Rheumatol 34 3 493 500 17295441 1:CAS:528: DC%2BD2sXktVCju7o%3D (Pubitemid 46364003)
53. S Nakano, et al. 2008 Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus Rheumatology (Oxford) 47 2 145 9 10.1093/rheumatology/kem327 1:CAS:528:DC%2BD1cXht1Shsb4%3D (Pubitemid 351168222)
54. ED Papadimitraki, et al. 2006 Expansion of Toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process Arthritis Rheum 54 11 3601 11 17075805 10.1002/art.22197 1:CAS:528:DC%2BD28Xht12mtLfN (Pubitemid 44737172)
55. L Bennett, et al. 2003 Interferon and granulopoiesis signatures in systemic lupus erythematosus blood J Exp Med 197 6 711 23 12642603 10.1084/jem.20021553 1:CAS:528:DC%2BD3sXitlOgs74%3D (Pubitemid 36350866)
56. SR Ytterberg TJ Schnitzer 1982 Serum interferon levels in patients with systemic lupus erythematosus Arthritis Rheum 25 4 401 6 6176248 10.1002/art.1780250407 1:STN:280:DyaL387ot1Cjtg%3D%3D (Pubitemid 12158948)
57. Y Ioannou DA Isenberg 2000 Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy Arthritis Rheum 43 7 1431 42 10902743 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E 1:CAS:528:DC%2BD3cXlsV2msbw%3D (Pubitemid 30452458)
58. M Visentini, et al. 2009 Regression of systemic lupus erythematosus after development of an acquired Toll-like receptor signaling defect and antibody deficiency Arthritis Rheum 60 9 2767 71 19714644 10.1002/art.24760 1:CAS:528:DC%2BD1MXht1WhtLbL Here an SLE patient is described to have long-term remission of disease after developing a CVID-like disease. Remission was due to a defect in TLR7 and TLR9 signaling that prevented the development of additional autoantibodies. This marks an important step in establishing a role for TLRs in human disease
59. JS Bates, et al. 2009 Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations Genes Immun 10 5 470 7 19387456 10.1038/gene.2009.31 1:CAS:528:DC%2BD1MXptVaru70%3D
60. SL Musone, et al. 2008 Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus Nat Genet 40 9 1062 4 19165919 10.1038/ng.202 1:CAS:528:DC%2BD1cXhtVGgtrfO
61. I Adrianto, et al. 2011 Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus Nat Genet 43 3 253 8 21336280 10.1038/ng.766 1:CAS:528:DC%2BC3MXit1ait7Y%3D
62. C Guiducci, et al. 2010 TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus Nature 465 7300 937 41 20559388 10.1038/nature09102 1:CAS:528:DC%2BC3cXnsVymtL8%3D This article shows that TLRs can impair steroid activity in lupus. This reinforces the importance of targeting TLRs to supplement current treatment options in SLE
63. FJ Barrat, et al. 2005 Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus J Exp Med 202 8 1131 9 16230478 10.1084/jem.20050914 1:CAS:528:DC%2BD2MXhtFelu7vO (Pubitemid 41464506)
64. O Duramad, et al. 2005 Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation J Immunol 174 9 5193 200 15843514 1:CAS:528:DC%2BD2MXjsVertrw%3D (Pubitemid 40593156)
65. FJ Barrat, et al. 2007 Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms Eur J Immunol 37 12 3582 6 18034431 10.1002/eji.200737815 1:CAS:528:DC%2BD1cXhsVegsw%3D%3D
66. L Dong, et al. 2005 Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice Arthritis Rheum 52 2 651 8 15692999 10.1002/art.20810 1:CAS:528:DC%2BD2MXit1Gjtbc%3D (Pubitemid 40216332)
67. RD Pawar, et al. 2007 Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus J Am Soc Nephrol 18 6 1721 31 17460144 10.1681/ASN.2006101162 1:CAS:528:DC%2BD2sXnt1Squ78%3D (Pubitemid 46870309)
68. K Oda H Kitano 2006 A comprehensive map of the Toll-like receptor signaling network Mol Syst Biol 2 2006 0015 10.1038/msb4100057 (Pubitemid 43948158)
69. T Bartfai, et al. 2003 A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses Proc Natl Acad Sci U S A 100 13 7971 6 12799462 10.1073/pnas.0932746100 1:CAS:528:DC%2BD3sXlt1Wqt7g%3D (Pubitemid 36760079)
70. M Loiarro, et al. 2005 Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B J Biol Chem 280 16 15809 14 15755740 10.1074/jbc.C400613200 1:CAS:528:DC%2BD2MXjtleisL0%3D (Pubitemid 40616701)
71. F Capolunghi, et al. 2010 Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients Rheumatology (Oxford) 49 12 2281 9 10.1093/rheumatology/keq226 1:CAS:528:DC%2BC3cXhsVejsbvL MyD88 inhibition impairs autoantibody production. B cells from SLE patients were stimulated with CpG in the presence or absence of the MyD88 inhibitor ST2825. The inhibitor suppressed the development of plasma cells and the production of autoantibodies, suggesting TLR inhibition as an adequate treatment of SLE
72. N Suzuki, et al. 2002 Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4 Nature 416 6882 750 6 11923871 10.1038/nature736 1:CAS:528:DC%2BD38XjtVKksb4%3D (Pubitemid 34429152)
73. TW Kim, et al. 2007 A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity J Exp Med 204 5 1025 36 17470642 10.1084/jem.20061825 1:CAS:528:DC%2BD2sXlsFSjsbc%3D (Pubitemid 46798147)
74. Z Wang, et al. 2009 IRAK-4 inhibitors for inflammation Curr Top Med Chem 9 8 724 37 19689377 10.2174/156802609789044407 1:CAS:528:DC%2BD1MXhtFehsLnO
75. MK Crow 2007 Type I interferon in systemic lupus erythematosus Curr Top Microbiol Immunol 316 359 86 17969456 10.1007/978-3-540-71329-6-17 1:CAS:528:DC%2BD1cXhs12rtLk%3D
76. L Ronnblom V Pascual 2008 The innate immune system in SLE: type I interferons and dendritic cells Lupus 17 5 394 9 18490415 10.1177/ 0961203308090020 1:STN:280:DC%2BD1czislWqsA%3D%3D (Pubitemid 351798715)
77. •• Merrill, J.T., et al., Safety profile and clinical activity of sifalimumab, a fully human anti-interferon {alpha} monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis, 2011. This article shows the potential effectiveness of sifalimumab, a monoclonal antibody directed toward IFN-α. Phase 1 clinical data describe trends toward decreased SLEDAI scores and fewer flares in SLE patients treated with sifalimumab.
78. TH Chuang RJ Ulevitch 2004 Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors Nat Immunol 5 5 495 502 15107846 10.1038/ni1066 1:CAS:528:DC%2BD2cXjsV2gurk%3D (Pubitemid 38660461)
79. Q Xie, et al. 2007 Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth Mol Immunol 44 14 3453 61 17477969 10.1016/j.molimm.2007.03.018 1:CAS:528:DC%2BD2sXlsFaisbg%3D (Pubitemid 46754450)
80. A Lartigue, et al. 2009 Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus J Immunol 183 10 6207 16 19841185 10.4049/jimmunol.0803219 1:CAS:528:DC%2BD1MXhtlKhsbnM